课题基金 / 基金详情

Role of Rho/Rho-kinase-mediated pathway in the pathogenesls of atherosclerosis

Role of Rho/Rho-kinase-mediated pathway in the pathogenesls of atherosclerosis
Rho/Rho激酶介导的通路在动脉粥样硬化发病机制中的作用
批准号:
13307024
负责人:
SHIMOKAWA Hiroaki
金额:
$35.19万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003

项目摘要

项目成果

SHIMOKAWA Hiroaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
(1)We have demonstrated that Rho/Rho-kinase-mediated pathway plays an important role in the pathogenesis of hypertension.(2)We have demonstrated that Rho-kinase-mediated pathway is substantially involved in the pathogenesis of angiotensin II-induced cardiovascular hypertrophy in rats.(3)We have demonstrated that Rho-kinase is located downstream of PKC in the signal transduction of vascular smooth muscle for coronary spasm in a porcine model.(4)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of in-stent restenosis in porcine coronary arteries.(5)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of LV remodeling after myocardial infarction in mice through inhibition of the expression of inflammatory cytokines.(6)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of monocrotaline-induced pulmonary hypertension in rats.(7)We have demonstrated that Rho-kinase is substantially mediated in the pathogenesis of microvascular angina.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
Matsumoto Y, ---, Shimokawa H.: "Long-term inhibition of Rho-kinase suppresses Neointimal formation after stent implantation In porcine coronary arteries -Involvement of Multiple mechanisms-"Arteriosclerosis, Thrombosis and Vascular Biology. 24. 181-186 (
Matsumoto Y, ---, Shimokawa H.:“长期抑制 Rho 激酶可抑制猪冠状动脉支架植入后的新内膜形成 - 多种机制的参与 -”动脉硬化、血栓形成和血管生物学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shimokawa H: "Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases"Journal of Cardiovascular Pharmacology. (in press). (2002)
Shimokawa H:“Rho激酶作为治疗心血管疾病的新型治疗靶点”心血管药理学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takemoto M, et al.: "Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase"Circulation. 106. 57-62 (2002)
Takemoto M 等人:“Rho 激酶介导缺氧诱导的内皮一氧化氮合酶下调”循环。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masumoto A, Mohri M, Shimokawa H, et al.: "Suppression of coronary artery spasm by a Rho-kinase inhibitor fasudil in patients with vasospastic angina"Circulation. 105. 1545-1547 (2002)
Masumoto A、Mohri M、Shimokawa H 等人:“Rho 激酶抑制剂法舒地尔对血管痉挛性心绞痛患者的冠状动脉痉挛的抑制作用”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
22
    The possibility of pleiotropic effects of Novel Oral Anticoagulants (NOAC) on Rho-kinase-cyclophilin A System
    • 批准号:
      25670379
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2013
    • 负责人:
      SHIMOKAWA Hiroaki
    • 依托单位:
    The role of SmgGDS in the pleiotropic effects by statins
    • 批准号:
      23659071
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      SHIMOKAWA Hiroaki
    • 依托单位:
    Molecular mechanisms for NOSs-mediated responses in microvessels
    • 批准号:
      22390154
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2010
    • 负责人:
      SHIMOKAWA Hiroaki
    • 依托单位:
    Experimental and Clinical Studies on the Significance of Endothelium-Derived Hyperpolarizing Factor (EDHF)
    海外基金